Introduction
============

Esophageal carcinoma is the ninth most prevalent cancer in the word [@B1] and has an estimated 5-years survival rate of 10% [@B2]. Radiotherapy is an import component in the management of esophageal carcinoma for pre-operative and definitive treatment. For esophageal carcinoma, due to complex of planning target volume are surrounded by many organs at risks (OARs) such as spinal cord, lung, heart and liver, radiotherapy has shift from 3D conformal radiation therapy (3D-CRT) to advanced radiotherapy such as intensity modulated radiation therapy (IMRT) and volumetric modulated arc treatment (VMAT) for the clinical benefits of increasing dose to tumor and sparing organs at risk (OARs). Several studies have demonstrated that volumetric modulated arc therapy has the ability to reduce monitor units and treatment time when compared with intensity-modulated radiation therapy \[3.4.5.6\].

Recently, there has been a growing interesting in operating medical linear accelerators without a flattening filter (FFF). The main advantages of FFF beams are increased dose rate, reduced scatter radiation, reduced leaf transmission and treatment head leakage [@B7]. Numerous literatures reported that the increased dose rate of FFF beams is particularly beneficial for stereotactic body radiotherapy (SBRT) due to reduction of the treatment times of large fraction doses \[8.9,10\]. Plenty of literatures reported that VAMT plan was able to provide similar target coverage for esophageal carcinoma while reducing monitors units and treatment times compared to IMRT plan [@B11],[@B12]. Gabriele Kragl pointed out that removing the flattening filter lead to reduced peripheral doses for advanced treatment techniques [@B9]. So it\'s necessary to study whether benefits exist in esophageal carcinoma radiotherapy using flattening filter free (FFF) compared to flattened (FF) beams. The purpose of this study is to make a well comparison of dosimetric characteristics and delivery efficiency of treatment plan for esophageal carcinoma using flattening filter free (FFF) and flattened (FF) beams.

Materials and Methods
=====================

Patients
--------

The data of twenty eight esophageal carcinoma patients who underwent VMAT technique under VersaHD unit (Elekta AB, Stockholm, Sweden) were randomized selected from our database and fully anonymized for the purpose of this study. The biopsy results showed that all patients were squamous cell carcinoma. Each patient had received 60Gy for PTV1 and 50Gy for PTV2 in total 28 fractions, with a dose of 2.14Gy given for PTV1 each weekday. The clinical information for each patient is listed in Table [1](#T1){ref-type="table"}.

Computed tomography (CT) simulation
-----------------------------------

For each patient, the serious CT scans were performed using a Philips Brilliance CT Big Bore (Phillips Medical System, 96 Highland Heights, OH, USA). Patients were immobilized using a body vacuum pillow and scanned with head first and supine on position. The reconstruction slice thickness is 5mm and region scanned extended from the cricothyroid membrane to the lower edge of liver. All patients CT images were transmitted to Monaco treatment planning system (TPS) (Monaco V5.0.2, Elekta AB, Stockholm, Sweden) to delineate the target volumes and organs at risk (OARs) and design the treatment plan.

Delineation of anatomy structures
---------------------------------

All organ structures were delineated by trained physician. The gross tumor volume (GTV) of esophageal tumor was including the esophageal tumor and the metastasis lymph nodes. The clinical target volume (CTV) was defined as 3.0 cm cranial-caudal margin and 1.0 cm margin in other direction. Regional lymphatic drainages were covered by the CTV, which included the para-esophagus, medial,and upper mediastinal lymph nodes. When the primary tumor was located in the cervical or the supper thoracic esophagus, the supraclavicular lymph nodes were included. For the patients with lower thoracic esophageal carcinoma, the pericardial lymph node was included. Planning target volumes (PTVs), which included PTV1 and PTV2, were generated by 5mm outer margin of GTV and CTV. The OARs, including the spinal cord, lung, heart, liver, were contoured following anatomic definitions.

Radiotherapy plans
------------------

A VMAT plan with FFF beam was created by directly changing the original plan radiation energy 6MV (6 Megavoltage with FF beam) to 6FFF (6 MV with FFF beam) and maintaining the original plan optimization parameters unchanged. And then the optimization was performed inversely using original plan parameters and dose were calculated using Monte Carlo (MC) algorithm with 3% of dose statistical uncertainty per control point and 3mm of voxel grid size. All original VMAT plans used a single full arc of 360° gantry rotation from -180 to 180 in clockwise direction. The max dose rate was set to 600 MU/min for 6 MV and 1400 MU/min for 6 FFF. The couch angle was set to 0 degree. And collimator was set to 15° to minimize the contribution of tongue and groove effect during the arc rotation.

Plan evaluation
---------------

All plans were produced with Monaco treatment planning system (Monaco V5.0.2, Elekta AB, Stockholm, Sweden) and this allowed for all dose volume histograms (DVHs) to be obtained with the same sampling algorithm and evaluation of plans based on the standard DVH. For the PTVs, the parameters analyzed were D ~2%~, D ~98%~, V ~100%~, V ~95%~, and homogeneity index (HI) and conformal index (CI). The algorithm for CI (19) and HI (18) were described as following.

PTV~95%~ is the planning target volume that received 95% of the prescribed dose, PTV is the planning target volume and V~95%~ is the volume that received 95% of the prescribed dose.

D~5%~ and D~98%~ indicate the doses that covered 5% and 98% of the PTV volume, respectively.

For the OARs, the parameters analyzed included as following: (1) Lung: the volume of Lung receiving dose at least 30, 20 and 10 Gy (V~30Gy~,V~20Gy~,V~10Gy~);(2)Heart: the volume of heart receiving dose at least 40 and 30 Gy( V~40Gy~,V~30Gy~), and mean heart dose (D~mean~);(3)Spinal cord: the maximum dose covering 1 cc volume of the spinal cord( D~1cc)~.

Peripheral doses around PTVs were analyzed via comparison of volume outside PTV2 covered by 45 Gy, 30 Gy, and 20 Gy (V~45Gy~, V~30Gy~,V~20Gy~).

Delivery efficiency comparison
------------------------------

Machine units (MUs) and treatment times were collected for delivery efficiency comparison, and median dose rates were also abstracted from log file for comparison. For VersaHD unit, the operation system (Version 3.1) contain one sub function named record graphic, which can record the information about actual delivery for chosen key words with the sample frequency of 4 times per second and can saved data as .xls format.

Statistical analysis
--------------------

The SPSS 19.0 software (IBM, Chicago, IL) was used for statistical data management and analysis. To determine statistical significance, the paired-sample *T* test was performed with *P* values \<0.05 considered significant. Student t test was also performed. Data are presented as the mean over all patients with standard deviations (SD).

Results
=======

Patient characteristics
-----------------------

Twenty eight esophageal carcinoma patients (27 men, 1 female) were selected. The median age was 61.8 years (range, 45-79years). According to the sixth edition of the classification by the International Union Against Cancer (UICC, 2002), 4 patients had stage II tumors, 12 patients had stage III tumors and 12 patients had stage IV tumors.

PTV dose
--------

The averaged volumes of these randomized selected twenty eight patients were 184.4 cc (ranged from 53 cc to 502cc) for PTV1and 621.3 cc (ranged from 192.6cc to 975 cc) for PTV2, respectively. The target dose coverage were compared in Table [2](#T2){ref-type="table"}, the results indicated there is no significant statistical discrepancy between 6FF and 6FFF in target dose coverage for plan comparison. The examples of representative dose distribution and DVHs for esophageal carcinoma cases are showed in Fig. [1](#F1){ref-type="fig"} and Fig. [2](#F2){ref-type="fig"}.

OAR dose
--------

For esophageal carcinoma, the bilateral lung, heart and spinal cord are priority considered constrained organs in OARs. The key parameters comparison listed in Table [2](#T2){ref-type="table"}, the result showed there is no significant discrepancy between plans with 6FF beam and 6FFF beam. Only the mean dose of heart is a slightly decreasing with 6 FFF compared to 6FF mode.

Peripheral doses volume
-----------------------

For peripheral dose around PTV2, a significant reduction of V~45Gy~, V~30Gy~ and V~20Gy~ were observed on average by 6.46%, 8.18% and 4.40%, respectively.

Delivery efficiency comparison
------------------------------

Generally, the 6 FFF plans have a significantly higher numbers of MUs by 21.83% compared to 6 FF plans, in contrast, the a significantly reduction of delivery time of 11.90% was observed for 6 FFF plans.

Discussion
==========

For comparison convenient, the specific points on the DVH curve, HI and CI index were chosen for evaluation of treatment plan quality in this study. Table [2](#T2){ref-type="table"} showed that both FF beams and FFF beams can achieve a comparable dose distribution in targets. The D~2%~ which indicated hot dose in targets were 6416.3cGy and 6420.4cGy for FF beams and FFF beams, respectively, both bellowed 108% of prescripts dose. While the percentage volume of prescripts dose covered were much similar both for PTV1 and PTV2, with FF beams and FFF beams. Only the CI index in PTV2 was significant different, the averaged FFF plans CI index was 3.98% higher than FF beam plans mainly due to reduction of volume covered by the dose (V~95%~) outside PTV2.

For esophagus carcinoma, the pulmonary toxicity is a serious possible side-effect of treatment. So the dose constrain to bilateral lung is priority to consider for evaluation of treatment plans. Numerous literatures had been published with conflicting parameters for prediction of pulmonary toxicity [@B13],[@B14], but it was still quite difficult to make comparison between studies. In this study, the V~10Gy~, V~20Gy~ and V~30Gy~ were used for evaluation of pulmonary toxicity. Mary V.G stated when the total lung V~20Gy~ is \<25%, the very low risk of pneumonitis would occur [@B15]. For these two contrast plan groups with FF beams and FFF beams, the average values of V~20Gy~ and V~30Gy~ are both very close, meanwhile, the V~20Gy~ is less than 30% and V~30Gy~ is less than 20%, they are all within dose constrain tolerance and no significant statistic difference for both plans. But this isn\'t indicating that there isn\'t a significant difference in special case such showed in Fig. [1](#F1){ref-type="fig"}.

The heart dose constrain is the second considered organ for esophagus carcinoma [@B16]. Plenty of studies have observed substantial radiation-induced heart disease when the heart received more than 40 Gy and that the reduction of V~40Gy~ was pertinent in reducing heart toxicities [@B17]. In this study, the V~40Gy~ of FFF beam plan was 10.63%, a slightly decreasing compared to FF beam plan of 12.1%. Wei et al stated that pericardial effusion occurred for patients only 13% of the time when V~30Gy~ to the heart was kept below 46% [@B18]. In this study, the average V~30Gy~ for the heart were 25.3% and 23.1% for FF beams and FFF beams, respectively. They are all below 46%. Although the V~40Gy~,V~30Gy~ of FFF beams plans had a slightly decreasing trend compared to the FF beams plans, they were all within 3%. However, the average mean dose of the heart had significant difference, the FFF beam plans was bellowed 3.22% compared to FF beam plans.

Spinal cord is a dose strict constrained organ for esophagus carcinoma, it also should be spared from target when radiation fields involving the neck, thorax, abdomen and pelvis. John P.K et al stated that a total spinal cord dose of 50 Gy, 60 Gy, and \~69 Gy were associated with a 0.2%,6% and 50% rate of myelopathy for conventional fraction dose of 2 Gy per day [@B19]. In our clinic practice, the dose constrain for spinal cord was that the D~max~ less than 50 Gy or D~1cc~ less than 45 Gy. In this study, the average D~1cc~ of spinal cord were 42.18 Gy for FF beam plan and 42.11 Gy for FFF beam plan, respectively. There is no significant difference between these two type beam plans.

Peripheral dose around PTV2 were significant different. For FFF beam plans, the peripheral dose such as V~45\ Gy~, V~30\ Gy~ and V~20Gy~ were reduced by 6.46%, 8.18% and 4.40%, respectively compared to the FF beam plans. The organs at risk, such as lung, heart, stomach, trachea, and throat, spinal cord as so on which located around target would be benefit from peripheral dose reduction. Gabriele Kragl et al stated that the peripheral dose were in general smaller for treatment plans calculated with FFF beams [@B9]. They also measured the dose with 20 cm distance from the field edge, the result showed that the FFF beam reduced dose about 23% on average for SBRT plans compared with 6 FF beams. There are many reasons contributed to the peripheral dose reduction. For FFF beam mode, the major source of scattered radiation was removed. It has a great impact on the field outside dose exposure. The scanned profiles showed that FFF beam had the same trend as for FF beam in penumbra region, but the dose fall-off was more pronounced and the values were generally lower for FFF beams. In Vassiliev et al studies, they observed the peripheral dose reduction of 15% at a depth of 5 cm and 2cm distance from static 4x4 cm^2^ field edge [@B20]. The dose fall-off also was different and the values were generally lower for FFF beams. In fact, the small fields are more likely to show a distinct reduction of peripheral dose [@B21].

As reported in most previously studies, the time reduction and MUs numbers increasing were also found in our plan comparison [@B22],[@B23]. The MUs numbers increasing were mainly due to achieve a homogeneous dose distribution the FFF beam shape needs to be compensated by a higher number of small segments and MUs. The delivery time reduction mainly resulted from the higher mean dose rates delivery. However, the delivery time were restricted by gantry rotation speed and MLC leaf movement speed. In our studies, the average delivery dose rates were higher 31.32% compared to 323.3 MU/min of FF beams plans. Ines Lohse et al [@B24] irradiated U87-MG and T98G cells using 10 MV FF beams and FFF beams at same dose level using different dose rates, the result indicated that the higher the dose rates, the more decreasing the cell surviving fraction. They also irradiated these cells at different dose levels using a dose rates of 400 MU/min, the results showed that they couldn\'t see any difference in cell kill at a dose level of 5 Gy, but a statistically significant reduction of clonogenic survival were observed compared to the treatment with FF beams at a dose of 10 Gy, and the higher the single dose, the more pronounced the cancer cell survival diverges within two beams. The result indicated that the use of the FFF beam more efficiently decreases tumor cell survival. This phenomenon can benefit for higher dose SBRT regiments.

However, the plan comparison was conducted by same optimization parameters settings. This could limit the plans quality. In future work, the effort to reduce the numbers of MUs and segments of FFF beams could be developed, this can go step further to decrease the peripheral dose around target.

Conclusion
==========

For esophagus carcinoma, the most distinctive character of FFF beam plans was reduction of peripheral dose around targets while the dose distribution in targets were comparable, this can benefit for the OARs located around targets.

![Dose distributions from VMAT of patient 3 with FF beam (Left) and FFF beam (Right).](jcav09p3263g001){#F1}

![Cumulative DVHs for patients 3 for PTV1, PTV2,lungs,heart, spinal cord and normal tissue (body minus PTV2) obtained in FF beam VMAT plan(solid lines) and FFF beamVAMT plan (dash lines).](jcav09p3263g002){#F2}

###### 

Patient\'s characteristics and target volume.

  -----------------------------------------------------------------------
  Patients   Staging   Gender   Age    PTV1\            PTV2\
                                       volume (cm^3^)   volumes (cm^3^)
  ---------- --------- -------- ------ ---------------- -----------------
  1          T2N1M0    M        79     125.24           410.48

  2          T2N1M0    M        51     179.855          776.235

  3          T2N3M0    M        53     126.425          736.19

  4          T2N1M0    M        68     117.39           447.895

  5          T2N1M1    M        73     153.81           485.195

  6          T3N1M1    M        51     136.54           452.54

  7          T2N1M1    M        65     183.215          602.45

  8          T3N0M0    M        56     445.98           903.175

  9          T2N3M0    M        61     318.14           645.775

  10         T3N1M1    M        58     282.46           823.08

  11         T3NIM0    M        49     184.98           611.405

  12         T2N1M1    M        51     502.045          961.765

  13         T2N1M0    M        64     91.475           572.33

  14         T2N3M0    M        64     149.155          754.925

  15         T2N1M0    M        61     286.28           804.935

  16         T4N0M0    M        59     225.27           661.485

  17         T3N1M1    M        45     82.031           644.185

  18         T4N1M0    M        62     125.895          570.99

  19         T3N1M0    F        49     135.765          616.805

  20         T2N1M0    M        75     54.685           443.09

  21         T3N2M0    M        78     52.975           192.575

  22         T3N1M1    M        63     101.3            642.26

  23         T4N1M0    M        68     200.68           701.775

  24         T2N1M0    M        67     418.695          975.74

  25         T3N3M0    M        57     91.605           449.025

  26         T4N1M0    M        79     145.1            526.84

  27         T3N1M1    M        66     84.085           472.97

  28         T3N1M1    M        60     62.34            509.59

  Mean                          61.8   184.4            621.3
  -----------------------------------------------------------------------

###### 

Averaged over 28 patients DVH parameters, homogeneity, uniformity indices for the PTVs and OAR DVH parameters with p- and t- values for comparison.

                            Parameters           6 FF-Plan        6 FFF-Plan    *p*     t        Δ(%)
  ------------------------- -------------------- ---------------- ------------- ------- -------- --------
  PTVs dose                 PTV1-D~2%~(cGy)      6416.3±93.0      6420.4±78.7   0.578   -0.56    0.08%
  PTV1-D~98%~(cGy)          5933.0±102.5         5925.1±104.5     0.478         0.72    -0.13%   
  PTV1-V~95~ (%)            99.7±0.5             99.6±0.5         0.619         -0.50   -0.1%    
  PTV1-V~100~ (%)           95.95±2.9            95.8±3.0         0.655         0.45    -0.15%   
  HI                        1.06±0.02            1.060±0.02       0.475         -0.72   0.14%    
  CI95%                     0.453±0.13           0.451±0.12       0.566         0.58    -0.43%   
  PTV2-D~98%~ (cGy)         4917.5±133.44        4869.3±138.1     0.015         2.60    -0.98%   
  PTV2-V~95~ (%)            98.94±0.7            98.7±0.9         0.088         1.77    -0.24%   
  PTV2-V~100~ (%)           96.8±2.0             96.1±2.2         0.008         2.88    -0.7%    
  CI95%                     0.618±0.05           0.643±0.05       0.000         -4.99   3.98%    
  OARs dose                 **Bilateral lung**                                                   
  V30Gy(%)                  12.4±4.1             11.7±3.5         0.008         2.85    -0.64%   
  V20Gy(%)                  24.8±7.6             24.3±6.5         0.240         1.20    -0.5%    
  V10Gy(%)                  52.3±14.3            52.4±14.0        0.883         -0.15   0.16%    
  **Heart**                                                                                      
  V40Gy(%)                  12.1±9.4             10.6±8.8         0.008         2.88    -1.48%   
  V30Gy(%)                  25.3±19.4            23.1±18.3        0.013         2.67    -2.16%   
  Dmean(cGy)                1901.8±1010.9        1840.6±1015.6    0.008         2.85    -3.22%   
  **Spinal cord**                                                                                
  D1cc(cGy)                 4217.9±238.8         4210.7±221.5     0.638         0.48    -0.17%   
  Peripheral doses volume   V45Gy(cc)            789±440          738±414       0.000   4.77     -6.46%
  V30Gy(cc)                 1984±804             1822±718         0.000         4.48    -8.18%   
  V20Gy(cc)                 3510±1213            3355±1129        0.000         4.28    -4.40%   
  Delivery efficiency       MUs                  594.5.19±150.5   724.2±191.3   0.000   -7.87    21.83%
  Time                      109.1±12.8           96.1±9.93        0.000         10.58   -11.9%   
  Mean Dose Rate            323.3±47.72          424.5±82.5       0.000         -10.4   31.3%    
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